You are here

Article Text

Article menu
Download PDFPDF
Regional Anesthesia and Acute Pain: Original Articles
Effect of topical morphine on acute and chronic postmastectomy pain: what is the optimum dose?
  1. Sahar Abdel-Baky Mohamed, MD*,
  2. Hala Saad Abdel-Ghaffar, MD†,
  3. Shereen Mamdouh Kamal, MD*,
  4. Khaled Mohamed Fares, PhD* and
  5. Hesham Mahmoud Hamza, MD‡
  1. *Department of Anesthesia, Intensive Care and Pain Management, South Egypt Cancer Institute
  2. †Department of Anesthesia and Intensive Care, Faculty of Medicine
  3. ‡Department of Surgery, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
  1. Address correspondence to: Hala Saad Abdel-Ghaffar, MD, Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Assiut, Egypt 0715715 (e-mail: hallasaad{at}yahoo.com).

Abstract

Background and Objectives Poorly controlled postoperative pain is strongly associated with the development of chronic pain. We aimed to investigate the effect of topical morphine (in 1 of 3 doses: 5, 10, or 15 mg) on acute and chronic neuropathic pain after modified radical mastectomy for cancer breast.

Methods In this registered clinical trial (ClinicalTrials.gov identifier: NCT02462577), 90 patients were allocated to receive 10 mL plain bupivacaine 0.5% plus either 5, 10, or 15 mg morphine (designated by the group names Morphine5, Morphine10, and Morphine15, respectively). The combination was diluted by saline 0.9% to 20 mL and irrigated in the wound before skin closure. Groups were compared for the following: time to first postoperative analgesia; intravenous patient-controlled analgesia (PCA) morphine consumption; pain scores; hemodynamics; sedation; adverse events in first postoperative 48 hours; and Leeds Assessment of Neuropathic Symptoms and Signs scores in first and third postoperative months.

Results No patient in the Morphine15 group requested postoperative PCA morphine versus 19 and 8 in the Morphine5 and Morphine10 groups, respectively (P < 0.002). Time to first analgesic request and total consumption of PCA morphine analgesia were 7.31 ± 3.12 hours versus 14.00 ± 3.54 hours (P < 0.000) and 1.42 ± 0.50 mg versus 1.00 ± 0.00 mg (P = 0.371) in the Morphine5 and Morphine10 groups, respectively. Lowest scores on visual analog pain scale at rest (P < 0.001) and visual analog pain scale during movement (P < 0.01) were recorded in the Morphine15 group, followed by Morphine10 then Morphine5 group. Lowest Leeds Assessment of Neuropathic Symptoms and Signs scores were recorded in the Morphine15 group in the first month (1.10 ± 0.37 vs 5.76 ± 3.26 and 4.73 ± 2.87, P < 0.0001) and third postoperative month (4.40 ± 1.77 vs 6.33 ± 3.21 and 5.43 ± 2.67, P < 0.006) compared with Morphine5 and Morphine10 groups, respectively. No patient in the Morphine15 group developed chronic pain versus 4 and 2 in Morphine5 and Morphine10 groups, respectively.

Conclusions Topical morphine controlled acute postmastectomy pain in a dose-dependent manner and reduced the incidence and severity of chronic postmastectomy pain syndrome.

https://doi.org/10.1097/AAP.0000000000000496

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This study is attributed to South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

      Support was provided solely from departmental resources.

      The authors declare no conflict of interest.

      Trial Registration: ClinicalTrials.gov identifier: NCT02462577.